REPORT DESCRIPTION
Plasmapheresis Device Market – Overview
Plasmapheresis is a procedure in which blood is separated into cells and plasma (liquid). The plasma is
then removed and replaced with fresh frozen plasma. It is done to treat variety of autoimmune disorders
such as myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, sickle cell anemia,
guillain-barre syndrome, and lambert- eaton myasthenic syndrome where autoantibodies are generated
harming the body. Plasmapheresis can stop this growth of auto antibodies by removing the plasma that
contains antibodies and replacing it with new plasma. Plasmapheresis can be performed using a
semipermeable membrane-based device in combination with hemodialysis equipment.
Strategies used by the key players such as acquisitions, is expected to boost growth of the plasmapheresis
device market. For instance, on September 2018, Shire plc. (SHP) acquired sanaplasma AG, augmenting
plasma collection network. The acquisition of sanaplasma AG is expected to increase Shire's access to
plasma in the longer term and also widens its European plasma collection network, complementing existing
core capabilities in plasma supply and manufacturing. This will also help to increase the customer base in
the European region which in turn will raise demand for Plasmapheresis devices in the market.